Acryl eze 93 a

The enteric-coated tablets were prepared by first admixing 66.63% niclosamide ASD granules, 13.1% microcrystalline cellulose (Ceolus^® PH-102, Asahi Kasei Chemical Corporation, Tokyo, Japan), 8.8% croscarmellose sodium (Kiccolate^TM, Nichirin Chemical Industries, LTD., Dojima, Japan), 0.28% magnesium stearate (Spectrum Chemical, New Brunswick, NJ, USA), and 11.1% sodium chloride (Fisher Chemical, Ottawa, ON, Canada). The blend was filled into a hopper placed on a Stoke F4 Press. The tablet cores were produced using a 10 mm round standard cup tooling and with a target final tablet core weight of 428 mg. Then, the tablet cores were added to a Vector LDCS-Hi Coater (Vector Corporation, Marion, IA, USA). Opadry II Clear (Colorcon, West Point, PA, USA) dispersion in either water or 20:80 water/ethanol mixture was used for seal coating to a target weight gain of 3%. Then, the sub-coated tablets were enteric coated with either a completely water-based coating (Acryl-EZE^® 93 A, Colorcon, West Point, PA, USA) or a mixture of water and ethanol-based coating (Opadry^® Enteric, Colorcon, West Point, PA, USA) to a target 10% weight gain.

MEDI7219 was manufactured by Bachem (Bubendorf, Switzerland). The permeation enhancers Na CDC and PG were purchased from Sigma-Aldrich (St. Louis, MO, USA). Eudragit polymers and PlasACRYL HTP 20 were purchased from Evonik (Allentown, PA, USA). Mucoadhesive polymer Carbopol 71G was purchased from Lubrizol (Wickliffe, OH, USA). HPMC Hypromellose K4M and Acryl-eze 93A were purchased from Colorcon (Harleysville, PA, USA). Glyceryl behenate was purchased from Gattefossé (Eschbach, Germany). Hydrogenated castor oil was purchased from BASF (Ludwigshafen, Germany). Low-substituted hydroxypropyl cellulose (LH-21 and LH-32) was purchased from Shin-Etsu (Tokyo, Japan). Simethicone was purchased from Basildon (Abingdon, UK). All other ingredients were purchased from Sigma-Aldrich. The OralogiK time-delayed tablets were designed and manufactured by BDD Pharma (Scotland, UK).